Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Low BCL11A Expression in the Myeloma Microenvironment at Diagnosis Is Associated with Early Development of MDS Cytogenetic Abnormalities and Poor Overall Survival

Bounleut Phanavanh, Priyangi Malaviarachchi, Adam Rosenthal, Yogesh Jethava, MB, MRCP, MD FRCPath, Bart Barlogie, MD PhD, Jeffrey Sawyer, PhD, Joshua Epstein, DSc, Shmuel Yaccoby, PhD, Sarah K. Johnson, PhD

Blood (2014) 124 (21): 2012.

https://doi.org/10.1182/blood.V124.21.2012.2012

Published: 2014

Journal Articles

Evidence of an Epigenetic Origin for High-Risk 1q21 Copy Number Aberrations in Multiple Myeloma

Jeffrey Sawyer, PhD, Erming Tian, PhD, Christoph Heuck, MD, Donald Johann, MD MS, Joshua Epstein, DSc, Charles Swanson, Janet Lukacs, Regina Lichti Binz, Gael Sammartino, Maurizio Zangari, MD, Frits van Rhee, MD PhD, Bart Barlogie, MD, PhD

Blood (2014) 124 (21): 725.

https://doi.org/10.1182/blood.V124.21.725.725

Published: 2014

Journal Articles

Cytogenetic Features Of Patients With Monoclonal Gammopathy Of Undetermined Significance (MGUS) and Asymptomatic Multiple Myeloma (AMM)

Erming Tian, PhD, Sarah Waheed, MD, Jeffrey Sawyer, PhD, Qing Zhang, PhD, Christoph Heuck, MD, Madhav V. Dhodapkar, MD, Bart Barlogie, MD, PhD, Joshua Epstein, DSc

Blood (2013) 122 (21): 3108.

https://doi.org/10.1182/blood.V122.21.3108.3108

Published: 2013

Journal Articles

Role Of Cytogenetic Abnormalities At Baseline and During 5-Year Follow-Up In Multiple Myeloma Patients Treated On The Total Therapy 3 Protocol

Sarah Waheed, MD, Jeffrey Sawyer, PhD, Adam Rosenthal, Frits van Rhee, MD, PhD, Nathan M Petty, MS, Saad Z Usmani, MD, FACP, Clyde Bailey, Christoph Heuck, MD, Antje Hoering, PhD, Bart Barlogie, MD, PhD

Blood (2013) 122 (21): 3137.

https://doi.org/10.1182/blood.V122.21.3137.3137

Published: 2013

Journal Articles

Total Therapy (TT) Studies For Gene Expression Profiling (GEP)-Defined High-Risk Multiple Myeloma

Christoph Heuck, MD, Frits van Rhee, MD, PhD, Alan Mitchell, Adam Rosenthal, Sarah Waheed, MD, Nathan M Petty, MS, Clyde Bailey, Ryan Williams, Ryan van Laar, PhD, Susan B. Panozzo, BS, Jeffrey Sawyer, PhD, John Crowley, PhD, Bart Barlogie, MD, PhD

Blood (2013) 122 (21): 126.

https://doi.org/10.1182/blood.V122.21.126.126

Published: 2013

Journal Articles

Secondary Myelodysplasia-Associated Metaphase Cytogenetic Abnormalities in Newly Diagnosed Multiple Myeloma Treated On Total Therapies 2 & 3– Influence of Cumulative Dosing of Maintenance Drugs

Saad Z Usmani, MD FACP, Adam Rosenthal, Rachael Sexton, Antje Hoering, Zeba N Singh, MD, Sarah Waheed, MD, Al-Ola Abdallah, MD, Jameel Muzaffar, MD, Nathan M Petty, John Crowley, PhD, Jeffrey Sawyer, PhD, Joshua Epstein, DSc, Frits van Rhee, MD, PhD, Bart Barlogie, MD, PhD

Blood (2012) 120 (21): 324.

https://doi.org/10.1182/blood.V120.21.324.324

Published: 2012

Journal Articles

FISH and GEP Based Prediction of Chromosomal Translocation Identifies Myeloma Patients Who Do Not Benefit From Bortezomib

Erming Tian, Qing Zhang, Christoph Heuck, MD, Shweta S. Chavan, PhD, Jeffrey Sawyer, PhD, Saad Z Usmani, MD FACP, Joshua Epstein, DSc, Bart Barlogie, MD, PhD

Blood (2012) 120 (21): 1814.

https://doi.org/10.1182/blood.V120.21.1814.1814

Published: 2012

Journal Articles

Prediction of Cytogenetic Abnormalities in Multiple Myeloma Based on Gene Expression Profiles

Yiming Zhou, PhD, Qing Zhang, PhD, Christoph Heuck, MD, Owen Stephens, Erming Tian, PhD, Jeffrey Sawyer, PhD, Marie-Astrid Cartron-Mizeracki, MS, Bart Barlogie, MD, PhD, John D Shaughnessy, Jr., PhD

Blood (2011) 118 (21): 629.

https://doi.org/10.1182/blood.V118.21.629.629

Published: 2011

Journal Articles

Only Concomitant Presence of Cytogenetic Abnormalities in Randomly Sampled Bone Marrow and in MRI-Defined Focal Lesions Imparts Poor Prognosis and Is Associated with Gene Expression Profiling (GEP)-Based High-Risk Myeloma.

Bijay Nair, PhD, Yiming Zhou, PhD, Bart Barlogie, MD, PhD, Jeffrey Sawyer, PhD, Jackie Szymonifka, John Crowley, PhD, John D. Shaughnessy, Jr., PhD

Blood (2008) 112 (11): 1691.

https://doi.org/10.1182/blood.V112.11.1691.1691

Published: 2008

Journal Articles

Metaphase Cytogenetics Adds to Gene Expression Profiling in the Identification of High Risk Multiple Myeloma.

Guido Tricot, MD, PhD, Fenghuang Zhan, MD, PhD, Bart Barlogie, MD, PhD, Yongsheng Huang, PhD, Jeffrey Sawyer, PhD, John Shaughnessy, PhD

Blood (2006) 108 (11): 114.

https://doi.org/10.1182/blood.V108.11.114.114

Published: 2006

Journal Articles

Identification of Three Novel Chromosomal Translocation Partners Involving the Immunoglobulin Loci in Newly Diagnosed Myeloma and Human Myeloma Cell Lines.

Ichiro Hanamura, MD, Shinsuke Iida, MD, Ryuzo Ueda, MD, Michael Kuehl, MD, Contance Cullraro, Leif Bergsagel, MD, Jeffrey Sawyer, PhD, Bart Barlogie, MD, PhD, John Shaughnessy, Jr., PhD

Blood (2005) 106 (11): 1552.

https://doi.org/10.1182/blood.V106.11.1552.1552

Published: 2005

Journal Articles

A Complete Remission (CR) Is Not a Prerequisite for Prolonged Survival after Autotransplants for Multiple Myeloma.

Guido Tricot, MD, PhD, Maureen Reiner, PhD, Jeffrey Sawyer, PhD, John Crowley, PhD, Bart Barlogie, MD, PhD

Blood (2004) 104 (11): 926.

https://doi.org/10.1182/blood.V104.11.926.926

Published: 2004

Journal Articles

Low Incidence of Cytogenetically-Defined MDS/AML among Newly Diagnosed Patients Treated According to Total Therapy 1 (TT 1) or Total Therapy 2 (TT 2).

Raymond Thertulien, MD, PhD, Bart Barlogie, MD, PhD, Jeffrey Sawyer, PhD, Clyde Bailey, Maureen Reiner, Erik Rasmussen, Athanasios Fassas, MD, Maurizio Zangari, MD, Guido Tricot, MD, PhD

Blood (2004) 104 (11): 940.

https://doi.org/10.1182/blood.V104.11.940.940

Published: 2004

NARROW

Low BCL11A Expression in the Myeloma Microenvironment at Diagnosis Is Associated with Early Development of MDS Cytogenetic Abnormalities and Poor Overall Survival

Evidence of an Epigenetic Origin for High-Risk 1q21 Copy Number Aberrations in Multiple Myeloma

Cytogenetic Features Of Patients With Monoclonal Gammopathy Of Undetermined Significance (MGUS) and Asymptomatic Multiple Myeloma (AMM)

Role Of Cytogenetic Abnormalities At Baseline and During 5-Year Follow-Up In Multiple Myeloma Patients Treated On The Total Therapy 3 Protocol

Total Therapy (TT) Studies For Gene Expression Profiling (GEP)-Defined High-Risk Multiple Myeloma

Secondary Myelodysplasia-Associated Metaphase Cytogenetic Abnormalities in Newly Diagnosed Multiple Myeloma Treated On Total Therapies 2 & 3– Influence of Cumulative Dosing of Maintenance Drugs

FISH and GEP Based Prediction of Chromosomal Translocation Identifies Myeloma Patients Who Do Not Benefit From Bortezomib

Prediction of Cytogenetic Abnormalities in Multiple Myeloma Based on Gene Expression Profiles

Only Concomitant Presence of Cytogenetic Abnormalities in Randomly Sampled Bone Marrow and in MRI-Defined Focal Lesions Imparts Poor Prognosis and Is Associated with Gene Expression Profiling (GEP)-Based High-Risk Myeloma.

Metaphase Cytogenetics Adds to Gene Expression Profiling in the Identification of High Risk Multiple Myeloma.

Identification of Three Novel Chromosomal Translocation Partners Involving the Immunoglobulin Loci in Newly Diagnosed Myeloma and Human Myeloma Cell Lines.

A Complete Remission (CR) Is Not a Prerequisite for Prolonged Survival after Autotransplants for Multiple Myeloma.

Low Incidence of Cytogenetically-Defined MDS/AML among Newly Diagnosed Patients Treated According to Total Therapy 1 (TT 1) or Total Therapy 2 (TT 2).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only